Cardiac electrophysiology is an evolving field that relies heavily on costly device- and catheter-based technologies. An increasing number of patients with heart rhythm disorders are becoming eligible for cardiac interventions, not least due to the rising prevalence of atrial fibrillation and increased longevity in the population. Meanwhile, the expansive costs of healthcare face finite societal resources, and a cost-conscious approach to new technologies is critical. Cost-effectiveness analyses support rational decision-making in healthcare by evaluating the ratio of healthcare costs to health benefits for competing therapies. They may, however, be subject to significant uncertainty and bias. This paper aims to introduce the basic concepts, framework, and limitations of cost-effectiveness analyses to clinicians including recent examples from clinical electrophysiology and device therapy.
Keywords: Antibacterial envelope; Cardiac electrophysiology; Cardiac implantable electronic devices; Cost utility; Cost-effectiveness analysis; Early rhythm control; Economy; Quality-adjusted life year.
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.